Neuronetics Recognizes Critical Health Professionals During Mental Health Awareness Month - Seite 3

To join the conversation during Mental Health Awareness Month and honor those fostering these important conversations and delivering invaluable care, follow NeuroStar on Facebook, Instagram and Twitter, and access additional resources on YouTube. For more information about NeuroStar Advanced Therapy, visit www.neurostar.com.

About Neuronetics
Neuronetics, Inc. (or the “Company”) is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product is a transcranial magnetic stimulation (TMS) device called the NeuroStar Advanced Therapy System. Additional information can be found at www.neuronetics.com.

About NeuroStar Advanced Therapy
NeuroStar Advanced Therapy is the market leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation, and the #1 TMS choice of doctors for patients with Major Depressive Disorder (MDD). Widely available across the United States, NeuroStar is reimbursed by most commercial and government health plans, including Medicare and Tricare.

In the U.S., NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan's national health insurance.

In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were 4.2 times more likely to achieve remission compared to patients receiving sham treatment (P = 0.02; odds ratio = 4.05).⁶ The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head.

NeuroStar is a registered trademark of Neuronetics, Inc. (NASDAQ:STIM). For more information and full safety and prescribing information, visit www.neurostar.com.

Media Contact:
Chelsey Manko
Office: 610-455-2778
[e-mail]

¹ https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml, accessed 1/16/2018
² Kessler RC, et al. (2003), JAMA
³ Gaynes BN, et al. (2008), Cleveland Clinic Journal of Medicine
⁴ Post A, et al. (2001), J Psychiatric Research
⁵ Liston C, et al. (2014), Biol Psychiatry
⁶ George MS, et al. (2010), Arch Gen Psychiatry